Baseline serum cortisol as a prognostic biomarker for immune checkpoint inhibitor therapy in advanced gastric cancer - Takeaways - MDSpire

Baseline serum cortisol as a prognostic biomarker for immune checkpoint inhibitor therapy in advanced gastric cancer

  • By

  • Yufei Zhao

  • Zhanjun Guo

  • Jingjing Zhang

  • Zhidong Zhang

  • May 13, 2026

Share

  • 1

    Baseline serum cortisol levels are significantly associated with immune checkpoint inhibitor efficacy in advanced gastric cancer patients.

  • 2

    High baseline cortisol correlates with poorer disease control rate, progression-free survival, and overall survival in advanced gastric cancer.

  • 3

    The study identified a cutoff of 193.95 nmol/L for baseline cortisol, with an AUC of 0.673 for overall survival prediction.

  • 4

    Multivariate analysis confirmed high baseline cortisol as an independent prognostic factor for poorer overall survival.

  • 5

    This research supports further exploration of stress hormone signaling to optimize immunotherapy in advanced gastric cancer.

Original Source(s)

Baseline serum cortisol as a prognostic biomarker for immune checkpoint inhibitor therapy in advanced gastric cancer

  • by Yufei Zhao, Zhanjun Guo, Jingjing Zhang, Zhidong Zhang

  • May 13, 2026

Related Content

Mass Spec Roundup: Proteins, Lipids, Pitcher Plants, and Coffee

This week’s roundup explores hidden chemistry in the dark proteome, forest soils, lipid binding in cells, and pitcher plant food webs

  • May 13, 2026

  • 7 min
Maternal Screening Could Prevent Rare Leukemia

Targeted testing may reduce missed diagnoses and future cases

  • May 13, 2026

  • 2 min
This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min